ADAM9 and neoplasm: To further delineate the mechanism of LV-shADAM9 therapy-induced tumor growth inhibition, the cell cycle distribution between ADAM9-proficient PC3shGFP and ADAM9-deficient PC3shADAM9 cells cultured under serum-starvation or serum-supplemented (5% FBS) conditions were analyzed.